2022 capital drama: Pfizer, Merck have shot!

The hot mRNA field in 2021 will still have a "high fever" in 2022

mRNA attracts giants to compete for layout

Local enterprises urgently need hard-core innovation

In March 2021, Aibo Bio received 600 million yuan in Series B financing;

In April 2021, Bendao Gene raised 60 million yuan in Series A financing;

In May 2021, Qichensheng Biotechnology pre-A+ round of financing hundreds of millions of yuan;

In June 2021, Chuanxin Bio’s angel round of financing was nearly 100 million yuan;

In July 2021, Neighbor Bio Seed + round of financing exceeded 10 million yuan;

In July 2021, Shenxin Bio raised hundreds of millions of yuan in Series A financing;

In August 2021, Aibo Bio’s C-round financing exceeded US$700 million;

In November 2021, Aibo Biotech raised USD 300 million in its C+ round

It is not difficult to see that the domestic mRNA field is entering the "golden period" of the market
.
Gao Fu, director of the Chinese Center for Disease Control and Prevention, previously publicly stated that the current global vaccine research and development has entered a stage of "stuck in the brain"
.
"The success of mRNA vaccine research and development has given us unlimited room for imagination, and it has also given China an opportunity to overtake the world in the field of vaccinology; at the same time, we need to change traditional concepts and strengthen original innovation in the process of innovation
.
"High-value innovation , Breakthrough technology To solve the "stuck neck" problem, the essence is to solve the "stuck brain" problem behind these problems .
As more and more players enter this track, whether they have core technology, whether they have core intellectual property rights, and whether the innovation platform has the sustainable development ability of self-hematopoiesis, this is when latecomers face increasing competitive pressure.
The core issues that must be faced and considered .
Industry insiders said that mRNA drugs have the advantages of short duration of action, good safety, and wide range of uses.
The new crown epidemic has made mRNA technology shine, and it has become the world's most watched investment track .
Although the current mRNA track is hot, in fact, the innovation and transformation capabilities of domestic mRNA layout companies still need to be improved.
Whether the mRNA boom can continue in the future remains to be seen .